UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study

Annals of oncology, 2022-04, Vol.33 (4), p.406-415

2022

Volltextzugriff (PDF)

Biomarker analyses of second-line ramucirumab in patients with advanced gastric cancer from RAINBOW, a global, randomized, double-blind, phase 3 study

European journal of cancer (1990), 2020-03, Vol.127, p.150-157

2020

Volltextzugriff (PDF)

Ramucirumab combined with FOLFOX as front-line therapy for advanced esophageal, gastroesophageal junction, or gastric adenocarcinoma: a randomized, double-blind, multicenter Phase II trial

Annals of oncology, 2016-12, Vol.27 (12), p.2196-2203

2016

Volltextzugriff (PDF)

Circulating tumour cells as a biomarker for diagnosis and staging in pancreatic cancer

British journal of cancer, 2016-06, Vol.114 (12), p.1367-1375

2016

Volltextzugriff (PDF)

A phase II, randomised study of mFOLFOX6 with or without the Akt inhibitor ipatasertib in patients with locally advanced or metastatic gastric or gastroesophageal junction cancer

European journal of cancer (1990), 2019-02, Vol.108, p.17-24

2019

Volltextzugriff (PDF)

Phase II trial of modified FOLFOX6 and erlotinib in patients with metastatic or advanced adenocarcinoma of the oesophagus and gastro-oesophageal junction

British journal of cancer, 2011-09, Vol.105 (6), p.760-765

2011

Volltextzugriff (PDF)

Claudin18.who? Examining biomarker overlap and outcomes in claudin18.2-positive gastroesophageal adenocarcinomas

ESMO open, 2023-04, Vol.8 (2), p.100778-100778, Article 100778

2023

Volltextzugriff (PDF)

Consideration of an association between performance status and ramucirumab efficacy

Annals of oncology, 2017-04, Vol.28 (4), p.902-903

2017

Volltextzugriff (PDF)

A phase 1/2, open-label, dose-expansion study of liposomal irinotecan (nal-IRI) plus 5-fluorouracil/leucovorin (5-FU/LV) and oxaliplatin (OX) in patients with previously untreated metastatic pancreatic cancer

Annals of oncology, 2019-07, Vol.30, p.iv123-iv123

2019

Volltextzugriff (PDF)

Ramucirumab combined with FOLFOX as front-line therapy for advanced esophageal, gastroesophageal junction, or gastric adenocarcinoma: a randomized, double-blind, multicenter Phase II trial

Annals of oncology, 2019-12, Vol.30 (12), p.2016-2016

2019

Volltextzugriff (PDF)

Phase 1b open-label study evaluating the safety, pharmacokinetics, and preliminary efficacy of ABT-165 plus FOLFIRI in patients with second-line (2L) colorectal cancer (CRC)

Annals of oncology, 2018-06, Vol.29, p.v66-v66

2018

Volltextzugriff (PDF)

ABT-165 plus FOLFIRI vs bevacizumab plus FOLFIRI in patients with metastatic colorectal cancer (mCRC) previously treated with fluoropyrimidine/oxaliplatin and bevacizumab - Trial in progress

Annals of oncology, 2018-06, Vol.29, p.v83-v84

2018

Volltextzugriff (PDF)

Results of a phase I study of andecaliximab in combination with mFOLFOX6 and bevacizumab in patients with previously untreated metastatic colorectal cancer

Annals of oncology, 2018-10, Vol.29, p.viii189-viii190

2018

Volltextzugriff (PDF)

Pembrolizumab with or without chemotherapy versus chemotherapy for first-line treatment of advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: The Phase 3 KEYNOTE-062 Study

Annals of oncology, 2019-07, Vol.30, p.iv152-iv153

2019

Volltextzugriff (PDF)

Updated efficacy and safety data of dabrafenib (D) and trametinib (T) in patients (pts) with BRAF V600E–mutated anaplastic thyroid cancer (ATC)

Annals of oncology, 2018-10, Vol.29, p.viii645-viii646

2018

Volltextzugriff (PDF)

Responses and durability of clinical benefit in pancreatic ductal adenocarcinoma (PDAC) patients treated with pegilodecakin (AM0010) in combination with 5-FU/LV and oxaliplatin (FOLFOX)

Annals of oncology, 2018-10, Vol.29, p.viii406-viii406

2018

Volltextzugriff (PDF)

342 A Phase Ib/II study of alpelisib (BYL719) and ganitumab (AMG 479) in adult patients with selected advanced solid tumors

European journal of cancer (1990), 2015-09, Vol.51, p.S68-S68

2015

Volltextzugriff (PDF)

526 A Phase I study of the dual, intravenous (IV) phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) inhibitor PF-05212384 in combination with irinotecan in patients (pts) with colorectal cancer (CRC) and other advanced solid tumors

European journal of cancer (1990), 2014-11, Vol.50, p.171-171

2014

Volltextzugriff (PDF)

11LBA Phase I study of the selective BRAFV600 inhibitor encorafenib (LGX818) combined with cetuximab and with or without the α-specific PI3K inhibitor alpelisib (BYL719) in patients with advanced BRAF mutant colorectal cancer

European journal of cancer (1990), 2014-11, Vol.50, p.199-199

2014

Volltextzugriff (PDF)

A Multi-Disciplinary Cancer Program Enhances Hereditary Colorectal Cancer Detection

The Journal of surgical research, 2014-02, Vol.186 (2), p.504-504

2014

Volltextzugriff (PDF)

Ramucirumab plus pembrolizumab: can we make the maths work?

The lancet oncology, 2019-08, Vol.20 (8), p.1041-1043

2019

Volltextzugriff (PDF)

358 A Multi-arm Phase 1 Dose Escalation Study of Safety, Pharmacokinetics, and Pharmacodynamics of the Dual PI3K/mTOR Inhibitors PF-04691502 (oral) and PF-05212384 (IV) in Combination with the MEK Inhibitor PD-0325901 or Irinotecan in Patients with Advanced Cancer

European journal of cancer (1990), 2012-11, Vol.48, p.109-109

2012

Volltextzugriff (PDF)

Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor

The New England journal of medicine, 2015-07, Vol.373 (5), p.428-437

2015

Volltextzugriff (PDF)

Correction: Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer

PloS one, 2022-10, Vol.17 (10)

2022

Volltextzugriff (PDF)

P1.12-22 A Phase 1b/2 Study of Niraparib Plus Temozolomide Versus Standard Care as Maintenance Therapy in Extensive-Stage Small Cell Lung Cancer Patients

Journal of thoracic oncology, 2019-10, Vol.14 (10), p.S543-S543

2019

Volltextzugriff (PDF)

1 – 25 von 160

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(155)
Mit Volltextzugriff
(143)

Publikationsform

Artikel
(160)

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study

Biomarker analyses of second-line ramucirumab in patients with advanced gastric cancer from RAINBOW, a global, randomized, double-blind, phase 3 study

Ramucirumab combined with FOLFOX as front-line therapy for advanced esophageal, gastroesophageal junction, or gastric adenocarcinoma: a randomized, double-blind, multicenter Phase II trial

Circulating tumour cells as a biomarker for diagnosis and staging in pancreatic cancer

A phase II, randomised study of mFOLFOX6 with or without the Akt inhibitor ipatasertib in patients with locally advanced or metastatic gastric or gastroesophageal junction cancer

Phase II trial of modified FOLFOX6 and erlotinib in patients with metastatic or advanced adenocarcinoma of the oesophagus and gastro-oesophageal junction

Claudin18.who? Examining biomarker overlap and outcomes in claudin18.2-positive gastroesophageal adenocarcinomas

Consideration of an association between performance status and ramucirumab efficacy

A phase 1/2, open-label, dose-expansion study of liposomal irinotecan (nal-IRI) plus 5-fluorouracil/leucovorin (5-FU/LV) and oxaliplatin (OX) in patients with previously untreated metastatic pancreatic cancer

Ramucirumab combined with FOLFOX as front-line therapy for advanced esophageal, gastroesophageal junction, or gastric adenocarcinoma: a randomized, double-blind, multicenter Phase II trial

Phase 1b open-label study evaluating the safety, pharmacokinetics, and preliminary efficacy of ABT-165 plus FOLFIRI in patients with second-line (2L) colorectal cancer (CRC)

ABT-165 plus FOLFIRI vs bevacizumab plus FOLFIRI in patients with metastatic colorectal cancer (mCRC) previously treated with fluoropyrimidine/oxaliplatin and bevacizumab - Trial in progress

Results of a phase I study of andecaliximab in combination with mFOLFOX6 and bevacizumab in patients with previously untreated metastatic colorectal cancer

Pembrolizumab with or without chemotherapy versus chemotherapy for first-line treatment of advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: The Phase 3 KEYNOTE-062 Study

Updated efficacy and safety data of dabrafenib (D) and trametinib (T) in patients (pts) with BRAF V600E–mutated anaplastic thyroid cancer (ATC)

Responses and durability of clinical benefit in pancreatic ductal adenocarcinoma (PDAC) patients treated with pegilodecakin (AM0010) in combination with 5-FU/LV and oxaliplatin (FOLFOX)

342 A Phase Ib/II study of alpelisib (BYL719) and ganitumab (AMG 479) in adult patients with selected advanced solid tumors

526 A Phase I study of the dual, intravenous (IV) phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) inhibitor PF-05212384 in combination with irinotecan in patients (pts) with colorectal cancer (CRC) and other advanced solid tumors

11LBA Phase I study of the selective BRAFV600 inhibitor encorafenib (LGX818) combined with cetuximab and with or without the α-specific PI3K inhibitor alpelisib (BYL719) in patients with advanced BRAF mutant colorectal cancer

A Multi-Disciplinary Cancer Program Enhances Hereditary Colorectal Cancer Detection

Ramucirumab plus pembrolizumab: can we make the maths work?

358 A Multi-arm Phase 1 Dose Escalation Study of Safety, Pharmacokinetics, and Pharmacodynamics of the Dual PI3K/mTOR Inhibitors PF-04691502 (oral) and PF-05212384 (IV) in Combination with the MEK Inhibitor PD-0325901 or Irinotecan in Patients with Advanced Cancer

Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor

Correction: Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer

P1.12-22 A Phase 1b/2 Study of Niraparib Plus Temozolomide Versus Standard Care as Maintenance Therapy in Extensive-Stage Small Cell Lung Cancer Patients

Suchergebnisse filtern